Amgen Inc. Files SEC Form 424B2 with 3 Documents

Strategic Insights -

Amgen Inc., a leading biopharmaceutical company, has filed a U.S. Securities and Exchange Commission (SEC) form 424B2, a prospectus form required for primary offerings of securities, on August 16, 2022. The filing includes information on the security being offered, including the price and method of distribution. As a publicly-traded company, Amgen's filing with the SEC is a formal document or financial statement submitted for public record.

Key Takeaways:

  • Amgen Inc. filed an SEC form 424B2 on August 16, 2022, as part of a primary offering of securities.
  • The filing included 3 documents, with the SEC file number 0001193125-22-222425.
  • The contact information for Amgen is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320, with a phone number of (805)447-1000.
  • The SIC code for Amgen is 2836, Biological Products, (No Diagnostic Substances).
  • The filing is a requirement for primary offerings of securities and includes information on the security being offered, including the price and method of distribution.

Statistics:

  • August 16, 2022, is the date Amgen Inc. filed the SEC form 424B2.
  • The SEC file number is 0001193125-22-222425.
  • 3 documents were filed with the SEC form 424B2.
  • Amgen's SIC code is 2836, Biological Products, (No Diagnostic Substances).

Sources:

  • NewsRx, "U.S. Securities and Exchange Commission filing by Amgen Inc. (Form 424B2)" [1]
  • U.S. Securities and Exchange Commission, Form 424B2 [External link: https://www.sec.gov/Archives/edgar/data/318154/0001193125-22-222425-index.html]